Lantheus Holdings Inc. Common Stock (LNTH)
Stock · NASDAQ · Health Care
$99.7as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
LNTH Signal Track Record
How signals performed across all stocks →What LNTH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +0.3% | 50% | July 28, 2026 |
| Bollinger Band Breakout | 24 | -1.1% | 46% | June 25, 2026 |
| Bollinger Band Breakdown | 14 | +1.4% | 57% | September 22, 2026 |
| 200-Day Moving Average Touch | 12 | -1.3% | 50% | January 26, 2026 |
| Any 20-session window (baseline) | +1.1% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pu…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 1,193
- Website
- www.lantheus.com
Fundamentals
- 1-day range
- $100.23$100.72
- Market cap
- $6.58B
- P/E (trailing)
- 24.04
- P/E (forward)
- 15.89
- EPS (trailing)
- $4.18
- Dividend yield
- —
- Beta
- -0.03
- Avg. volume
- 1.33M
How Lantheus Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Lantheus Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LNTHLantheus Holdings Inc. Common Stock$99.7▼ 0.29%Market cap $6.58BP/E 24.04$49.67$111.86
- ORKAOruka Therapeutics Inc. Common Stock$71.93▼ 2.63%Market cap $5.94BP/E —$24.88$115.52
- CLDXCelldex Therapeutics Inc.$27.53▼ 4.84%Market cap $3.26BP/E —$22.1$45.14
- NEOGNeogen Corporation Common Stock$11.81▼ 3.75%Market cap $2.46BP/E —$5.37$14.26
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LNTH Lantheus Holdings Inc. Common Stock | $6.58B | 24.04 | $99.7 | ▼ 0.29% | $49.67$111.86 |
| ORKA Oruka Therapeutics Inc. Common Stock | $5.94B | — | $71.93 | ▼ 2.63% | $24.88$115.52 |
| CLDX Celldex Therapeutics Inc. | $3.26B | — | $27.53 | ▼ 4.84% | $22.1$45.14 |
| NEOG Neogen Corporation Common Stock | $2.46B | — | $11.81 | ▼ 3.75% | $5.37$14.26 |
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Gerard Ber · May 14, 2026 · Tax Withholding381 @ $96.67
- Mary Anne Heino · May 14, 2026 · Tax Withholding1.2K @ $96.67
- Phuong Khanh Morrow · May 14, 2026 · Grant4.1K
- Heinz Christoph Maeusli · May 14, 2026 · Grant4.1K
- Gary J. Pruden · May 14, 2026 · Grant4.1K
- Minnie Baylor-Henry · May 14, 2026 · Grant4.1K
- Gerard Ber · May 14, 2026 · Grant4.1K
- Julia Marie Eastland · May 14, 2026 · Grant4.1K
- Julie McHugh · May 14, 2026 · Grant4.1K
- James H. Thrall · May 14, 2026 · Grant4.1K
- Sam R. Leno · May 14, 2026 · Grant4.1K
- Daniel Niedzwiecki · April 17, 2026 · Tax Withholding1.9K @ $83.82
Institutional Ownership
March 31, 2026
- Total shares held
- 67.20M
- Total value held
- $4.97B
- Institutional holders
- 395
- Unknown8.18M
- Unknown5.58M
- Unknown4.77M
- Unknown4.63M
- Unknown2.91M
- Unknown2.43M
- Unknown1.78M
- Unknown1.77M
- Unknown1.65M
- Unknown1.56M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Lantheus Holdings receives Mizuho downgrade to neutral
Lantheus Holdings was downgraded to neutral by Mizuho, which also cut its price target to $109. The downgrade appeared alongside other recent analyst cuts highlighted in a Benzinga roundup of top downgrades. The new target sits near the current analyst consensus of $107.22 and close to the stock’s 52‑week high, while the RSI is around the midpoint.
Lantheus Holdings receives Mizuho downgrade to neutral. Lantheus Holdings was downgraded to neutral by Mizuho, which also cut its price target to $109. The downgrade appeared alongside other recent analyst cuts highlighted in a Benzinga roundup of top downgrades. The new target sits near the current analyst consensus of $107.22 and close to the stock’s 52‑week high, while the RSI is around the midpoint.